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Recently, Laia Tolosa and colleagues 
from Valencia University have published a 
study how to identify compounds that 
cause hepatotoxicity due to compromising 
mitochondrial functions (Tolosa et al., 
2015). The authors used a set of fluores-
cent probes for imaging: HepG2 cells were 
loaded with Hoechst 33342 for cell number 
determination, cell viability was deter-
mined with propidium iodid and Mito-
tracker Green FM was applied for quantifi-
cation of mitochondrial mass (Tolosa et al., 
2015). For a more detailed analysis of 
compromised mitochondria, the authors 
used Fluo-4 AM to detect changes in cyto-
plasmic free calcium, Mitotracker Deep 
Red for analysis of mitochondrial localiza-
tion, MitoSOX Red to analyze generation 
of superoxide by mitochondria, TMRM to 
study mitochondrial membrane potential 
and YO-PRO-1 for detection of apoptotic 
cells. Using this set of markers and quanti-
tative imaging techniques the authors clas-
sified a set of well-known mitochondrial 
hepatotoxicants with excellent accuracy 
(Tolosa et al., 2015). 
Drug or chemically induced liver injury 
represents a cutting-edge topic in toxicolo-
gy (Benet et al., 2014; Campos et al., 2014; 
Vitins et al., 2014; Liu et al., 2014; Godoy 
and Bolt, 2012; Vinken et al., 2012; Liang 
et al., 2011; Hammad et al., 2011). Nu-
merous research projects aim at establish-
ing in vitro systems to predict human hepa-
totoxicity (Chen et al., 2014; Grinberg et 
al., 2014; Carvalho et al., 2004; O’Brien et 
al., 2006; Reif, 2015; Shinde et al., 2015a, 
b; Kim et al., 2015; Pfeiffer et al., 2015). 
One of the limitations of current research is 
that it still remains challenging to predict 
doses that are associated with an increased 
risk of hepatotoxicity in vivo (Ghallab, 
2013; Reif, 2014). Moreover, cultivated 
cells undergo major changes compared to 
hepatocytes in an intact liver (Godoy et al., 
2015, 2013, 2009; Zellmer et al., 2010; 
Hewitt et al., 2007; Hengstler et al., 2000). 
Despite of the still remaining challenges 
the high-content screening platform estab-
lished by Tolosa and colleagues represents 
an important milestone. 
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